Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013)

AIDS

Volumn 28, Issue 13, 2014, Pages 1957-1965

  Klein, Marina B ^a,b   Rollet Kurhajec, Kathleen C ^a   Moodie, Erica E M ^c   Yaphe, Sean ^a   Tyndall, Mark ^b,d   Walmsley, Sharon ^b,e   Gill, John ^b,f   Martel Laferriere, Valerie ^g   Cooper, Curtis ^b,h  

^a MCGILL UNIVERSITY   (Canada)

^b Canadian HIV Trials Network   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f Southern Alberta HIV Clinic   (Canada)

^g CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^h OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Co infection; Deaths; Hepatitis C virus; HIV; Standardized mortality ratio

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CANADA; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG ABUSE; FEMALE; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; SMOKING; STANDARDIZED MORTALITY RATIO; VIRAL CLEARANCE; ADOLESCENT; ADULT; CLINICAL TRIAL; COMPLICATION; EPIDEMIOLOGY; HEPATITIS C, CHRONIC; HIV INFECTIONS; MIDDLE AGED; PROSPECTIVE STUDY; SURVIVAL;

ADOLESCENT; ADULT; CANADA; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84906548377     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000377     Document Type: Article

References (39)

1. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315:1194-1199.
2. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
3. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
4. Hogg RS, Yip B, Kully C, Craib K, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160:659-665.
5. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013; 8:e81355.
6. Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, et al. All-cause mortality in treated HIV-infected adults with CD4>/U500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012; 41:433-445.
7. Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Moller A, et al. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS 2004; 18:89-97.
8. Lewden C, Raffi F, Chene G, Sobel A, Leport C. Mortality in a cohort of HIV-infected adults started on a protease inhibitorcontaining therapy: standardization to the general population. J Acquir Immune Defic Syndr 2001; 26:480-482.
9. Keiser O, Taffe P, Zwahlen M, Battegay M, Bernasconi E, Weber R, et al. All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS 2004; 18:1835-1843.
10. Jaggy C, von Overbeck J, Ledergerber B, Schwarz C, Egger M, Rickenbach M, et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362: 877-878.
11. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95.
12. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 (Suppl 1):74-81.
13. Remis RS. Modelling the incidence and prevalence of hepatitis C infection and its sequelae in Canada. In Community Acquired Infections Division Centre for Communicable Disease and Infection Control: Public Health Agency of Canada; 2007.
14. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569.
15. Rosenthal E, Poiree M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17:1803-1809.
16. Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24:211-217.
17. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M. Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. Aids Res Hum Retrovirus 2001; 17: 1467-1471.
18. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-497.
19. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33:240-247.
20. Soriano V, Martin-Carbonero L, Garcia-Samaniego J, Puoti M. Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. Clin Infect Dis 2001; 33:1793-1795.
21. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42:799-805.
22. Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009; 49:1605-1615.
23. Tyndall MW, Craib KJ, Currie S, Li K, O'Shaughnessy MV, Schechter MT. Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr 2001; 28:351-357.
24. Deans GD, Raffa JD, Lai C, Fischer B, Krajden M, Amin J, et al. Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada. Can Med Assoc Open Access J 2013; 1:E68-E76.
25. Klein MB, Saeed S, Yang H, Cohen J, Conway B, Cooper C, et al. Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. Int J Epidemiol 2010; 39:1162-1169.
26. CHP. Protocol: coding causes of death in HIV protocol. 2013 (Version 2.3).
27. Kowalska JD, Friis-Moller N, Kirk O, Bannister W, Mocroft A, Sabin C, et al. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology 2011; 22:516-523.
28. Department of Demography UdMicwUoC, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). Canadian Human Mortality Database. Feb 19, 2008 [cited; http://www.bdlc.umontreal.ca/CHMD].
29. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526.
30. Lo Re VJ3rd, Lim JK, Goetz MB, Tate J, Bathulapalli H, Klein MB, et al. Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf 2011; 20:689-699.
31. Ulm K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol 1990; 131:373-375.
32. Amin J, LawMG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006; 368:938-945.
33. Grebely J, Raffa JD, Lai C, Krajden M, Kerr T, Fischer B, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16:352-358.
34. Hernando V, Perez-Cachafeiro S, Lewden C, Gonzalez J, Segura F, Oteo JA, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol 2012; 57:743-751.
35. McDonald SA, Hutchinson SJ, Bird SM, Mills PR, Dillon J, Bloor M, et al. A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. Stat Methods Med Res 2009; 18:271-283.
36. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72-77.
37. Berenguer J, Rodriguez E, Miralles P, Von Wichmann MA, Lopez-Aldeguer J, Mallolas J, et al. Sustained virological response to interferon plus ribavirin reduces nonliver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012; 55:728-736.
38. Tjepkema M, Wilkins R, Senecal S, Guimond E, Penney C. Mortality of Metis and registered Indian adults in Canada: an 11-year follow-up study. Health Rep 2009; 20:31-51.
39. Statistics Canada. Leading causes of death, by sex (Both sexes). 2012 2012-07-25 [cited 2013 April 4]. http://www.statcan.gc.ca/tables-tableaux/sum- som/l01/cst01/hlth36a-eng.htm.